Loading…
Lobbying Income
$1.4M
Filings
88
Unique Clients
2
Active Period
2007–2024
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Food and Drug Administration Amendments Act of 2007
2007 · mid_year · Client: RARE DISEASE THERAPEUTICS
To provide wiavers of product and facility user fees for small companies developing orphan drugs, as considered by HR 2900 and S 1082
Client expense: — · Firm income: $15,000
Matched citations: HR 2900
Food and Drug Administration Amendments Act of 2007
2007 · year_end · Client: RARE DISEASE THERAPEUTICS
To provide wiavers of product and facility user fees for small companies developing orphan drugs, as considered by HR 2900 and S 1082
Client expense: — · Firm income: —
Matched citations: HR 2900
Food and Drug Administration Amendments Act of 2007
2007 · mid_year · Client: RARE DISEASE THERAPEUTICS
To provide waivers of product and facility user fees for small companies developing orphan drugs, as considered by HR 2900 and S1082, FDA Reform legislation enacted in 2007
Client expense: — · Firm income: —
Matched citations: HR 2900
Source: Senate LDA